Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $6.61M
• Dividend Yield: N/A
• Average Volume (3M): 53.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 19.22%
• EPS Growth: 98.73%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.39
• Shares Outstanding: 4,555,945
• 10 Day Avg. Volume: 43,962
• 30 Day Avg. Volume: 53,602
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: -0.08
• Enterprise Value/Gross Profit: -0.27
• Enterprise Value/Ebitda: 0.57
• 1Y Price Target: $1.50
• Price Target Upside: 1.35% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $1.50 ▲(1.35% Upside)

Sunshine Biopharma's stock score is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates a lack of momentum, and the valuation is unattractive due to negative earnings and no dividend yield.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company may earn revenue through several key streams, including licensing agreements, partnerships with larger pharmaceutical firms for joint development efforts, and potential sales of its drug candidates upon successful regulatory approval. Additionally, SBFM may seek funding through grants or investments that support its research initiatives. Significant partnerships with research institutions or pharmaceutical companies can also enhance its revenue potential by providing access to additional resources, expertise, and markets.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma shows strong revenue growth, but persistent profitability challenges and negative cash flows highlight significant operational inefficiencies. The balance sheet is stable with positive equity, but profitability improvements are crucial for financial health.

Income Statement

Sunshine Biopharma has shown substantial revenue growth over the years, with a significant increase from $21,121 in 2019 to $34,874,283 in 2024. However, the company remains unprofitable, as indicated by negative EBIT, EBITDA, and net income figures across all years, which highlights ongoing operational challenges and cost management issues. The gross profit margin has improved, yet net profit margins remain negative, reflecting a need for better cost control and efficiency to reach profitability.

Balance Sheet

The balance sheet reveals a strong equity position with positive stockholders' equity in recent years, indicating some financial stability. However, the company has experienced fluctuating total assets and liabilities, and a history of negative equity in earlier years. The absence of debt in the latest period is a positive, yet the company's return on equity remains negative, which reflects ongoing profitability issues impacting shareholder value.

Cash Flow

Sunshine Biopharma's cash flow statement highlights a consistent struggle with negative operating and free cash flows, pointing to challenges in generating cash from its operations. Despite this, the company has managed to secure financing, as seen in positive financing cash flows, which have supported its liquidity. Improvements in free cash flow growth are necessary to ensure long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.87M	24.09M	4.35M	228.43K	71.41K
Gross Profit	10.67M	8.34M	1.70M	110.60K	45.56K
EBITDA	-5.15M	-3.82M	-26.45M	-12.10M	-2.60M
Net Income	-5.13M	-4.51M	-26.74M	-12.44M	-2.78M
Balance Sheet
Total Assets	30.56M	27.35M	29.24M	2.20M	1.05M
Cash, Cash Equivalents and Short-Term Investments	9.69M	16.29M	21.83M	2.05M	989.89K
Total Debt	952.48K	657.71K	4.27M	1.90M	1.91M
Total Liabilities	7.06M	6.14M	7.62M	1.99M	2.00M
Stockholders Equity	23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow
Free Cash Flow	-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
Operating Cash Flow	-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
Investing Cash Flow	-2.32M	-656.15K	-14.62M	0.00	-1.19K
Financing Cash Flow	9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.48, and below the 200-day MA of 2.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.96 is Neutral, neither overbought nor oversold. The STOCH value of 67.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
SNOA	51 Neutral	$7.92M	―	-78.73%	―	17.43%	75.52%
SBFM	46 Neutral	$6.61M	―	-25.65%	―	19.22%	98.73%
EVOK	46 Neutral	$8.43M	―	-152.92%	―	70.02%	82.33%
RDHL	41 Neutral	$3.12M	―	1155.92%	―	―	―
CPHI	41 Neutral	$4.50M	―	-52.05%	―	-29.64%	73.63%
PRFX	34 Underperform	$3.28M	―	-129.08%	―	―	―

Sunshine Biopharma Corporate Events

Sunshine Biopharma Strengthens Leadership with New Executive Agreements

Sunshine Biopharma Inc. has solidified its leadership team with new employment agreements for its top executives, effective January 1, 2024. Dr. Steve N. Slilaty, CEO, Camille Sebaaly, CFO, and Dr. Abderrazzak Merzouki, COO, will receive annual salary hikes tied to inflation or a minimum increase, whichever is higher. In case of termination without cause, substantial severance packages are promised, ensuring stability and confidence in the company’s future growth strategies.